Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)PREV STORYCrownBio Melancarkan Model Sasaran Disesuaikan Baharu untuk Imunoterapi